Pipeline

Immunocore has a robust pipeline of wholly-owned and partnered programmes spanning a broad range of disease indications.

Therapeutic areas

Oncology

Oncology overview

Within oncology, we are applying our ImmTAC® platform to overcome the limitations of current anti-cancer therapies to deliver:

  • Potent and specific re-direction of a patient’s own T cells to kill the target cancer cells.
  • Access to a pool of antigenic targets that is up to nine-fold greater than traditional antibody-based therapies.

This unique and potent mechanism of action provided by ImmTAC® molecules gives the potential to tackle diverse tumour types, including solid tumours that are characteristically immune excluded, or "cold" and thus resistant to the majority of existing immunotherapies that target activation of pre-existing immune cells. ImmTAC® molecules have the potential to convert "cold" tumours to "hot" through their T cell redirecting activity.

Beyond IMCgp100, we are continuing to apply our ImmTAC® technology to target a diverse range of cancer indications.

Uveal Melanoma

Uveal melanoma is an aggressive form of melanoma that arises from melanocytes in the uveal tract of the eye. Survival in uveal melanoma has remained largely unchanged since the early 1970s with the greatest burden in metastatic disease. Currently, there is no proven standard of care for metastatic uveal melanoma, meanwhile various therapies, including checkpoint inhibitors, are used without definitive evidence of benefit in this patient population.

IMCgp100 is designed to specifically target the melanoma-associated antigen gp100 and engages T cells to direct a potent and specific response against the cancer cell.

Infectious diseases

Infectious diseases

Visualisation of ImmTAV™-mediated killing of HIV-infected target cells

Infectious diseases overview

At Immunocore, we are applying our bi-specific T cell receptor (TCR) technology platform outside of oncology to the discovery of new treatments for infectious diseases that pose a global health challenge. Immune mobilising monoclonal TCRs against viruses or bacteria (ImmTAV™, ImmTAB™) molecules enable the immune system to recognise and kill diseased cells, in this case, virally or bacterially infected cells. Our initial target indications are HIV, chronic Hepatitis B and Tuberculosis (TB).

Our Infectious Diseases unit is deeply informed by our understanding of the mechanism of action of IMCgp100. We have also generated ex-vivo pilot data showing that HIV-directed ImmTAV™ molecules redirect ART-treated patient T cells to kill HIV-infected cells, even with low antigen copy numbers per cell (Yang et al, 2016).

ImmTAV™ and ImmTAB™ molecules have the potential to reduce treatment timelines, improve patient outcomes and ultimately "functionally cure" infections for which no cure exists today. The development of ImmTAV™/ImmTAB™ technology is supported by The Bill & Melinda Gates Foundation, with an investment of up to $40 million.

Autoimmune diseases

Autoimmune diseases

Autoimmune diseases overview

At Immunocore, we are expanding our bi-specific TCR- technology platform to target autoimmune diseases. ImmTAAI™ (Immune mobilising monoclonal TCRs against autoimmune disease) molecules constitute a targeted TCR fused to an effector function that is able to selectively trigger immune suppression in a tissue of interest and reconstitute the balance of the immune system.

Autoimmune diseases are often chronic and debilitating, and constitute an area of high unmet clinical need. We believe that this targeted approach has the potential to address many shortcomings of current treatment options, avoiding unwanted immune suppression in non-target tissues and deliver benefit to patients with limited treatment options.

Pipeline

Immunocore has a robust pipeline of wholly-owned and partnered programmes

Alongside high value proprietary programmes, Immunocore has co-discovery and co-development programmes with Lilly and discovery programmes, including milestones and royalties, with Genentech, GlaxoSmithKline and MedImmune (AstraZeneca).

Product

Indication

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Product

IMCgp100 Toggle

Indication

Uveal melanoma

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Product

IMCgp100 checkpoint combination Toggle

Indication

Cutaneous melanoma

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Product

GSK1 (IMCnyeso) Toggle

Indication

Synovial / Bladder / Melanoma / NSCLC

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Product

IMC-C103C Toggle

Indication

NSCLC / Oesophageal / Gastric / Head & Neck / Bladder

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Product

IMC-F106C Toggle

Indication

NSCLC / SCLC / Breast / Endometrial / Ovarian

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Product

IMC-G107C Toggle

Indication

Liver / NSCLC / Oesophageal / Gastric / Head & Neck / Bladder

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Product

Additional oncology programmes Toggle

Indication

Various

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Product

Partnered oncology programmes Toggle

Indication

Various

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Product

Infectious disease programmes Toggle

Indication

Various

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Product

Autoimmune programmes Toggle

Indication

Various

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Owner / Collaborator

Clinical trial locations

Europe

Europe

We have a number of clinical trials currently recruiting patients across Europe.

View all locations
North America

North America

We have a number of clinical trials currently recruiting patients across the US and Canada.

View all locations
Australasia

Australasia

We have a number of clinical trials currently recruiting patients across Australasia.

View all locations

Clinical trials information

We have a number of clinical trials currently recruiting patients.

Trial A Pivotal Study Investigating The Safety And Efficacy Of IMCgp100 Versus Investigator Choice In Advanced Uveal Melanoma (NCT03070392)

Conditions

Uveal Melanoma

View details

Trial A Phase 1 Study Of The Intra-Patient Escalation Dosing Regimen With IMCgp100 In Patients With Advanced Uveal Melanoma (NCT02570308)

Conditions

Uveal Melanoma

View details

Trial A Phase 1b/2 Study Of The Combination Of IMCgp100 With Durvalumab And/Or Tremelimumab In Cutaneous Melanoma (NCT02535078)

Conditions

Malignant Melanoma

View details

Trial IMCgp100-401 Rollover Study Designed To Provide Continued Access To IMCgp100 For Eligible Patients With Advanced Melanoma Who Have Previously Participated In An IMCgp100Study (NCT02889861)

Conditions

Malignant Melanoma

View details

Trial Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (NCT03515551)

Conditions

Melanoma

Advanced NSCLC

Urothelial Carcinoma and Synovial Sarcoma

View details

Further Information

For more information on clinical trials see clinicaltrials.gov.

If you are a medical professional and require further information about Immunocore, our clinical research or clinical trials, please send an email to medicalinformation@immunocore.com.

Patients should contact their doctor for information regarding any aspect of their treatment or involvement in clinical trials.